Xtalks released Issue 7 of our digital magazine for clinical research professionals, Xtalks Clinical Edge. This edition features 12 in-depth conversations that explore how evolving science, smarter trial design and patient insight are reshaping clinical development across therapeutic areas.
Since its launch, Xtalks Clinical Edge has become a trusted digital magazine for thought leadership in clinical research, connecting industry leaders across pharma, biotech and medtech with the ideas shaping how trials are conducted and translated into real-world impact.
Each issue delivers perspectives on how data, regulation and patient experience intersect in modern clinical research. With a readership of more than 86,000 engaged clinical trial professionals, the magazine continues to highlight the people and strategies advancing meaningful progress in clinical research.
Highlights from Xtalks Clinical Edge Issue 7
The seventh issue of Xtalks Clinical Edge features 12 conversations with leaders advancing clinical research across immunology, respiratory medicine, neurology, oncology, women’s health, dermatology, medtech and diagnostics.
Together, these stories reflect a shared focus on adapting clinical research to real-world complexity, where patient heterogeneity and meaningful measurement increasingly define success.
Immunology and Inflammatory Disease
In immunology, growing insight into disease drivers is pushing research toward upstream biological mechanisms aimed at achieving more durable disease control. AnaptysBio explores how targeting pathogenic immune cells — rather than single cytokines — may help restore immune balance in autoimmune and inflammatory diseases.
InflaRx examines how complement-targeted strategies, once largely focused on rare diseases, are expanding into broader inflammatory indications. Together, these conversations reflect how deeper biological insight is reshaping both therapeutic strategy and clinical trial design in immunology.
Respiratory Research
Respiratory disease is a major focus of this issue, particularly in conditions where delayed recognition and real-world complexity continue to impact outcomes.
Boehringer Ingelheim examines the urgent need to improve awareness, earlier diagnosis and disease characterization in idiopathic pulmonary fibrosis, alongside more patient-centered clinical research approaches. Connect Biopharma addresses a different but equally challenging aspect of respiratory research, exploring why acute asthma and COPD exacerbations remain difficult to study in emergency and urgent care settings, despite increasing clarity around inflammatory drivers.
Together, these perspectives show the need for trial designs that better reflect real-world care pathways and time-critical disease progression.
Neurology, Ophthalmology and Ischemic Disease
Several features in this issue examine disease areas where biological complexity and drug delivery continue to pose major challenges.
Dompé discusses unmet needs in optic neuropathies and what the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program could signal for accelerating development in neuro-ophthalmology by enabling earlier and more efficient regulatory review. Klotho Neurosciences examines the complexities of neurodegeneration research, including the manufacturing and delivery challenges associated with gene-based therapies.
DiaMedica expands this discussion into ischemic disease, exploring drug development for conditions such as stroke and preeclampsia, where safety, timing and clinically meaningful endpoints are paramount, and where therapeutic progress has historically lagged despite high unmet need.
Oncology and Women’s Health
In oncology and women’s health, Atossa Therapeutics reflects on how endocrine therapy development in ER-positive breast cancer is changing. The conversation highlights growing emphasis on long-term tolerability and adaptive clinical trial models designed to better reflect real-world biology and patient needs.
Data, Evidence and Global Access
Data-driven decision-making continues to shape modern clinical research, particularly in areas where traditional development models face limitations.
Takeda shares how real-world evidence (RWE), patient insights and human-focused AI are influencing trial design, evidence generation and access strategies, especially in rare diseases. Galderma examines how long-term data and RWE, alongside patient-reported outcomes, are redefining success metrics in dermatology and improving understanding of disease burden beyond visible symptoms.
Medtech and Diagnostics
This issue also highlights the growing role of medtech and diagnostics in advancing patient care and earlier intervention.
Medtronic Neurovascular discusses persistent gaps in stroke care, from access and awareness to global disparities, and how innovation and partnerships are helping address these challenges. Augurex examines how biomarker-driven diagnostics could help close long-standing diagnostic delays in axial spondyloarthritis, demonstrating the potential of precision diagnostics to move care upstream.
Together, the stories in Issue 7 of Xtalks Clinical Edge offer a clear picture of an industry navigating increasing complexity, where success depends on aligning biology, data, regulation and patient experience.
Why Be Featured in Xtalks Clinical Edge
Xtalks Clinical Edge is a platform for leaders shaping the next generation of clinical research.
If your organization provides the technologies, services or expertise that enable innovation in clinical trials, Xtalks Clinical Edge offers a high-impact opportunity to share your perspective with a global audience of industry decision-makers.
Through executive interviews, thought leadership features and editorial storytelling, we collaborate with CROs, technology providers, patient engagement leaders and more to surface insights that resonate across the clinical research ecosystem.
By being featured, your organization can:
- Elevate its voice as a thought leader in pharma, biotech, medtech and diagnostics
- Highlight real-world impact through expert insights and data-driven strategies
- Reach a global audience of more than 86,000 clinical research professionals
To explore partnership or feature opportunities, connect with:
Gabriela Bravo, Global Director, Value Added Services, Xtalks
Email: [email protected]
Phone: +1 289-306-0359
Join or login to leave a comment
JOIN LOGIN